
Vælg din etiket
vises direkte på hætteglassetReta + Tesamorelin Blend
GLP-1
- Sendes fra Tyskland
Bestilling
- DHL med sporing
- Diskret emballage
Kort fortalt
Reta + Tesamorelin Blend i tal
Nøgletallene fra vores leksikon.
Hele leksikonopslaget- Type
- Injectable blendtriple agonist + GHRH analog
- Sizes
- 20 mg1 size in the shop
What studies show
All 4 sources in the lexiconRetatrutide phase 2 trial (obesity), 48 weeks, NEJM 2023 (opens in a new tab)
New England Journal of Medicine (PubMed PMID 37366315)Retatrutide systematic review + meta-analysis (878 patients), 2025 (opens in a new tab)
Proc (Bayl Univ Med Cent) (PubMed PMID 40291085)Tesamorelin phase 3 trial (visceral fat, HIV), 12 months (opens in a new tab)
J Acquir Immune Defic Syndr (PubMed PMID 20101189)
Anmeldelser
Hvad kunderne siger
Kun rigtige bestillinger, der indeholdt Reta + Tesamorelin Blend.
Alle anmeldelserDer er endnu ingen laboratorieanalyse for Reta + Tesamorelin Blend. Stem på denFå det testet selv, vi betaler halvdelenAlle laboratorieanalyser
Viden
Alt om Reta + Tesamorelin Blend
Detaljerede oplysninger kommer snart.
Dosering
Indlæser doseringsinformation …
Godt at have
Det har du brug for til den
Bakteriostatisk vand lægges automatisk i din kurv. Sprøjter og servietter med ét klik.
Insulinsprøjter
10 stk. · 5.50 €
Spritservietter
50 stk. · 10 €
Hvor meget vand?
Enheder på sprøjten til din hætteglasstørrelse.
Åbn beregneren →Is the Reta + Tesamorelin Blend approved or studied?
No. As of 26 October 2026 the registry ClinicalTrials.gov lists no trial with Retatrutide and tesamorelin together. Tesamorelin alone has been approved in the USA since 2010, Retatrutide is in phase 3 and not approved.
What is the catch with the fixed mix?
The two substances were studied on very different schedules: Retatrutide once a week, tesamorelin daily. In a 1:1 vial the ranges from both trial programmes cannot be matched at the same time. The entry therefore goes by the Retatrutide share.
What do the Retatrutide trials show?
In phase 2 body weight fell by 24.2 percent after 48 weeks at the highest study dose, by 2.1 percent on placebo. In phase 3 (TRIUMPH-1) it was 25.0 versus 3.9 percent after 80 weeks. A meta-analysis with 878 participants confirmed clear effects on weight and metabolic values.
What do the tesamorelin trials show?
In 806 patients with HIV and excess belly fat, visceral fat fell by 15.4 percent more than on placebo in 26 weeks, subcutaneous fat stayed nearly the same. IGF-1 rose, blood sugar stayed stable. Those who continued kept the effect to week 52.
Which side effects were seen with the components?
Retatrutide: mainly nausea, diarrhoea and other gastrointestinal effects, depending on the dose, plus a slight rise in heart rate. Tesamorelin: injection site reactions, joint and muscle pain, fluid retention and tingling. There is no safety profile for the blend.
Which trials are still running?
Nine phase 3 trials of Retatrutide are running, the largest on heart and kidney events until 2029. The phase 3 trials of tesamorelin were completed years ago. No trial of the blend is listed in the registry.
Relateret
Relaterede produkter
Tirzepatide
Peptider · GLP-1 & fedttab GLP-1 & fedttab
10 størrelser
Laboratorietestet
= fra 10 €/hætteglas
Retatrutide
Peptider · GLP-1 & fedttab GLP-1 & fedttab
11 størrelser
Laboratorietestet
= fra 16 €/hætteglas
Semaglutide
Peptider · GLP-1 & fedttab GLP-1 & fedttab
6 størrelser
Laboratorietestet
= fra 10 €/hætteglas
Mazdutide
Peptider · GLP-1 & fedttab GLP-1 & fedttab
2 størrelser
= fra 32 €/hætteglas
Reta + Tesamorelin Blend